FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to oncology, and concerns the use of rapamycin derivatives. For this purpose, an effective amount of 40-O-(2-hydroxyethyl)-rapamycin is administered as a monotherapy.
EFFECT: this provides effective treatment of solid kidney tumors due to the pronounced antiproliferative properties of this drug.
5 cl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2659725C2 |
| USE OF RAPAMYCIN DERIVATIVE | 2011 |
|
RU2483727C1 |
| INHIBITION OR PREVENTION OF DISTURBED ANGIOGENIC REGULATION WITH USING RAPAMYCIN DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING RAPAMYCIN DERIVATIVE | 2006 |
|
RU2445093C2 |
| CANCER MEDICAL TREATMENT | 2005 |
|
RU2325906C2 |
| COMBINATION AND METHOD FOR PROPHYLAXIS OF BREAST CANCER | 2002 |
|
RU2322981C2 |
| NANOPARTICLE, CONTAINING RAPAMYCIN AND ALBUMIN AS ANTI-CANCER AGENT | 2008 |
|
RU2483714C2 |
| NANOPARTICLE, CONTAINING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT | 2013 |
|
RU2678448C2 |
| BIOMARKERS | 2005 |
|
RU2429297C2 |
| BIOMARKER | 2005 |
|
RU2385944C2 |
| APPLICATION OF MEDICATIONS, BINDING EDG-RECEPTOR, IN TREATMENT OF CANCER DISEASE | 2008 |
|
RU2426555C2 |
